- Home
- DIAX vs LRMR Comparison
DIAX vs LRMR Comparison
Compare DIAX & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DIAX | LRMR |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 525.1M | 455.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | DIAX | LRMR |
|---|---|---|
| Price | $14.10 | $3.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 100.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 7.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.63 | $1.80 |
| 52 Week High | $15.85 | $6.42 |
Technical Indicators
Market Signals| Indicator | DIAX | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 28.89 |
| Support Level | $13.73 | $3.14 |
| Resistance Level | $14.45 | $3.78 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 10.26 | 9.49 |
Price Performance
Historical ComparisonAbout DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.